enGene Holdings Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ronald H. W. Cooper
- Full Time Employees
- 82
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4868 Rue Levy Montreal QC Canada H4R 2P1
- IPO Date
- Feb 1, 2022
- CIK
- 0001980845
- Website
- engene.com
- Similar Companies
- Business
- enGene Holdings Inc. (Nasdaq: ENGN) operates as a clinical-stage biotechnology company focused on mainstreaming genetic medicines through non-viral therapeutics delivered to mucosal tissues and other organs; its lead investigational product candidate, detalimogene voraplasmid (previously EG-70), comprises three gene cargos including two RIG-I agonists and IL-12, delivered via the proprietary Dually Derivatized Oligochitosan (DDX) platform for intravesical administration to elicit local immune responses in non-muscle invasive bladder cancer (NMIBC); the DDX platform supports additional urological targets and potential expansion into other disease areas with high unmet needs. Detalimogene targets BCG-unresponsive NMIBC with carcinoma in situ (CIS) and papillary-only disease in the pivotal Phase 2 LEGEND trial Cohort 1, BCG-naïve NMIBC with CIS in Cohort 2a, BCG-exposed NMIBC with CIS in Cohort 2b, and BCG-unresponsive papillary-only NMIBC in Cohort 3, with U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations. The company, founded in 1999, maintains headquarters in Montreal, Quebec, Canada, at 4868 Rue Levy, Suite 220, with a U.S. office in Boston, Massachusetts, and employs approximately 57 people serving primarily North American markets through community urology clinics. Recent developments include a $60 million private placement financing in October 2024 led by investors such as Deep Track Capital, Cormorant Asset Management, and OrbiMed to advance detalimogene development, pre-commercial activities, and DDX platform expansion into 2027; an oversubscribed $200 million private placement in February 2024 supporting the ongoing LEGEND trial and new R&D programs; a proposed public offering of common shares announced in November 2025; and completion of a business combination with Forbion European Acquisition Corp. in October 2023 that generated $138 million in gross proceeds to propel EG-70 (now detalimogene) into pivotal studies.
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
EnGene Therapeutics: The Selloff Creates An Opportunity
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC Transcript
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
enGene Announces Name Change to enGene Therapeutics Inc.
enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of “Moderate Buy” from Analysts
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference